Physicochemical Properties
| Molecular Weight | 632.11 |
| Exact Mass | 631.177 |
| CAS # | 2055597-39-0 |
| Related CAS # | ASN007;2055597-12-9 |
| PubChem CID | 124122603 |
| Appearance | White to off-white solid powder |
| Hydrogen Bond Donor Count | 4 |
| Hydrogen Bond Acceptor Count | 11 |
| Rotatable Bond Count | 8 |
| Heavy Atom Count | 43 |
| Complexity | 827 |
| Defined Atom Stereocenter Count | 1 |
| SMILES | S(C1C=CC=CC=1)(O)(=O)=O.CC1=CN=C(NC2CCOCC2)N=C1N1C=NC(C(=O)N[C@@H](C2C=C(F)C=C(Cl)C=2)CN)=C1 |
| InChi Key | JXWBNMQMMAONIH-GMUIIQOCSA-N |
| InChi Code | InChI=1S/C22H25ClFN7O2.C6H6O3S/c1-13-10-26-22(28-17-2-4-33-5-3-17)30-20(13)31-11-19(27-12-31)21(32)29-18(9-25)14-6-15(23)8-16(24)7-14;7-10(8,9)6-4-2-1-3-5-6/h6-8,10-12,17-18H,2-5,9,25H2,1H3,(H,29,32)(H,26,28,30);1-5H,(H,7,8,9)/t18-;/m1./s1 |
| Chemical Name | N-[(1S)-2-amino-1-(3-chloro-5-fluorophenyl)ethyl]-1-[5-methyl-2-(oxan-4-ylamino)pyrimidin-4-yl]imidazole-4-carboxamide;benzenesulfonic acid |
| Synonyms | ASN007 benzenesulfonate; ERK-IN-3 benzenesulfonate |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| Targets | ERK1; ERK2 |
| ln Vitro | In a variety of cell lines, ASN007 prevents the phosphorylation of ERK1/2 proteins like RSK1, FRA1, and Elk1 [1]. ASN007 has a bridging impact on the MAPK transport bridge system and has single-digit nanomolar anti-proliferative activity [1]. |
| ln Vivo | ASN007 (daily) displayed tumor growth suppression in numerous BRAF and KRAS mutant xenograft models in mice and was well tolerated under efficient simulation [1]. |
| References |
[1]. Abstract B150: ASN007, a novel oral ERK inhibitor, shows robust antitumor activity in RAS mutant cancer models. Molecular Cancer Therapeutics. 2018 Jan; 17(1). |
Solubility Data
| Solubility (In Vitro) |
DMSO: ~320 mg/mL (~506.2 mM) H2O: ~100 mg/mL (~158.2 mM) |
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 8 mg/mL (12.66 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 80.0 mg/mL clear DMSO stock solution to 400 μL of PEG300 and mix evenly; then add 50 μL of Tween-80 to the above solution and mix evenly; then add 450 μL of normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 8 mg/mL (12.66 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 80.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 8 mg/mL (12.66 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 80.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. Solubility in Formulation 4: 100 mg/mL (158.20 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication.  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.5820 mL | 7.9100 mL | 15.8200 mL | |
| 5 mM | 0.3164 mL | 1.5820 mL | 3.1640 mL | |
| 10 mM | 0.1582 mL | 0.7910 mL | 1.5820 mL |